# BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

> **NCT06383013** · PHASE2 · RECRUITING · sponsor: **Blue Blood Biotech Corp.** · enrollment: 96 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **BIOLOGICAL:** BB-101

## Key facts

- **NCT ID:** NCT06383013
- **Lead sponsor:** Blue Blood Biotech Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06383013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06383013, "BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06383013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*